Theranexus has enrolled the first patient for its Phase II clinical study of THN102 to treat excessive daytime sleepiness associated with narcolepsy in adult patients.

The Phase II study is being conducted as a double-blind, randomised, placebo-controlled trial, which will compare the safety and efficacy of two different doses of THN102 with an active comparator, modafinil, considered as the standard care to treat sleepiness in 48 narcolepsy patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The patients will be enrolled at three French centres known as the Montpellier Regional University Hospital, the Paris public hospital organisation APHP and Lille Regional University Hospital.

The study is mainly focused on achieving a decrease in sleepiness, which will be measured by the Epworth Sleepiness Scale (ESS).

"This new approach developed by Theranexus carries with it a real sense of hope for a better answer to the ever-weighty medical needs in narcolepsy."

Montpellier Regional University Hospital professor Yves Dauvilliers said: “This new approach developed by Theranexus carries with it a real sense of hope for a better answer to the ever-weighty medical needs in narcolepsy.

See Also:

“If we confirm in patients the data obtained in disease models, as well as in healthy, sleep-deprived volunteers, then THN102 will represent an interesting therapeutic option for treating our patients once it is on the market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Narcolepsy, also termed as Gelineau’s disease or Gelineau’s syndrome, is a rarely occurring neurological disease that causes excessive, uncontrollable daytime sleepiness frequently associated with cataplexy, sleep paralysis, hypnagogic hallucinations, and altered night's sleep.

THN102 is an advanced drug candidate in the Theranexus portfolio and is the first to represent a new class of innovative  therapeutic combinations that associate a neural activity modulator, in this case modafinil (Modiodal, Provigil), with a glial connexin modulator, which in the case of THN102 is low-dose flecainide.